Zedoresertib

DRUG2 trials

Sponsors

Debiopharm International SA

Conditions

Advanced Solid TumorAstrocytoma, Grade IIIGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Phase 1

Study of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors

RecruitingNCT04855656

Debiopharm International SAAdvanced Solid Tumor

Start: 2021-04-30End: 2028-06-01Target: 464Updated: 2026-10-28

A Study of Zedoresertib (Debio 0123) in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Zedoresertib (Debio 0123) in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

RecruitingNCT05765812

Debiopharm International SAGlioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III

Start: 2023-05-15End: 2028-09-01Target: 116Updated: 2026-10-28

Related Papers

Abstract CT022: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib in patients with advanced solid tumors harboring CCNE1, FBXW7, or PPP2R1A genomic alterations

Cancer Research2026-04-17

Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

Cancer Research2025-04-253 citations

A Phase II Trial of the WEE1 Inhibitor Adavosertib in <i>SETD2</i> <i>-</i> Altered Advanced Solid Tumor Malignancies (NCI 10170)

Cancer Research Communications2024-06-2611 citations

Abstract IA010: Targeting genome instability in cancer: Translating synthetic lethal biology into the clinic

Molecular Cancer Therapeutics2024-06-10

Abstract A017: Characterizing intratumoral heterogeneity of <i>CCNE1</i> amplification in ovarian cancer using digital pathology

Molecular Cancer Therapeutics2024-06-10

Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)

Journal of Medicinal Chemistry2024-02-0121 citations

Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with <i>CCNE1</i> amplification or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>

Molecular Cancer Therapeutics2023-12-0117 citations

Abstract A023: Preclinical development of PKMYT1 and WEE1 inhibitor combinations

Molecular Cancer Therapeutics2023-12-013 citations

Abstract B057: Preclinical development of PKMYT1 and ATR inhibitor combinations

Molecular Cancer Therapeutics2023-12-012 citations

Abstract B169: Retrospective baseline biomarker analyses in a first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib (RP-6306) in pts with advanced solid tumors harboring <i>CCNE1</i> amplification and/or deleterious alterations in <i>FBXW7</i> or <i>PPP2R1A</i>

Molecular Cancer Therapeutics2023-12-01

RTID-03. A PHASE 1/2 STUDY OF THE WEE1 INHIBITOR DEBIO 0123 IN COMBINATION WITH TEMOZOLOMIDE +- RADIOTHERAPY IN ADULTS WITH RECURRENT OR NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2023-11-011 citations

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.

2023-06-0567 citations

Abstract 2132: Tumor heterogeneity of <i>CCNE1</i> copy number assessed by fluorescence <i>in situ</i> hybridization (FISH) in ovarian and uterine cancers and correlation with cyclin E protein expression

Cancer Research2023-04-04

Abstract 5650: RP-6306, a novel PKMYT1 inhibitor, demonstrates synthetic lethality as monotherapy and in combination with gemcitabine in <i>CCNE1</i> amplified cancer cells

Cancer Research2022-06-151 citations